Keeping Expectations in Check With Immune Checkpoint Inhibitors, J. Clin. Oncol, vol.36, pp.1654-1657, 2018. ,
Impact of oncogenic pathways on evasion of antitumour immune responses, Nat. Rev. Cancer, vol.18, pp.139-147, 2018. ,
Rational design and identification of immuno-oncology drug combinations, Eur. J. Cancer, vol.95, pp.38-51, 2018. ,
Cancer immunotherapy comes of age, Nature, vol.480, pp.480-489, 2011. ,
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers, Clin. Cancer Res, vol.22, pp.4309-4321, 2016. ,
Effects of conventional therapeutic interventions on the number and function of regulatory T cells, Oncoimmunology, vol.2, p.27025, 2013. ,
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice, J Clin Invest, vol.121, pp.3100-3108, 2011. ,
The new era of nanotechnology, an alternative to change cancer treatment, Development and Therapy, vol.11, pp.2871-2890, 2017. ,
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs, Critical Reviews in Oncology/Hematology, vol.88, pp.504-513, 2013. ,
Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles, Expert Rev Clin Pharmacol, vol.11, pp.599-610, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02143589
Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy, Int J Nanomedicine, vol.10, pp.3663-3685, 2015. ,
Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells, Theranostics, vol.8, pp.1824-1849, 2018. ,
Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: Therapeutic benefits, toxicity, mechanistic insights, and translational considerations, Nanomedicine, vol.14, pp.977-990, 2018. ,
Myeloid Toxicity of Cancer Treatment, J Adv Pract Oncol, vol.3, pp.209-224, 2012. ,
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis, Onco Targets Ther, vol.11, pp.955-965, 2018. ,
Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab, Cancer Immunol. Immunother, vol.67, pp.1349-1353, 2018. ,
The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients, Cancer Res Treat, vol.50, pp.19-29, 2018. ,
The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma, Am. J. Clin. Oncol, vol.38, pp.259-265, 2015. ,
Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis, JCO, vol.35, pp.14512-14512, 2017. ,
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors), Eur. J. Cancer, vol.84, pp.202-211, 2017. ,
Immunological aspects of cancer chemotherapy, Nat. Rev. Immunol, vol.8, pp.59-73, 2008. ,
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin Cancer Res, vol.12, pp.1317-1324, 2006. ,
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis, Exp Hematol Oncol, vol.1, pp.1-9, 2012. ,
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia, J Clin Oncol, vol.31, pp.676-683, 2013. ,
, Vitro and In Vivo Evaluation of Lipofufol, a New Triple Stealth Liposomal Formulation of Modulated 5-Fu: Impact on Efficacy and Toxicity, vol.30, pp.1281-1290, 2013.
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer, JCO, vol.23, pp.7794-7803, 2005. ,
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia, Pharm. Res, vol.29, pp.2833-2844, 2012. ,
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer, Clin. Pharmacol. Ther, vol.102, pp.997-1005, 2017. ,
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann. Oncol, vol.29, pp.1437-1444, 2018. ,
Gut microbiome modulates efficacy of immune checkpoint inhibitors, J Hematol Oncol, vol.11, p.47, 2018. ,
Neoantigens in cancer immunotherapy, Science, vol.348, pp.69-74, 2015. ,
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy, Cancer Metastasis Rev, vol.30, pp.61-69, 2011. ,
Resistance to PD1/PDL1 checkpoint inhibition, Cancer Treat. Rev, vol.52, pp.71-81, 2017. ,
Immunogenic and tolerogenic cell death, Nat. Rev. Immunol, vol.9, pp.353-363, 2009. ,
In vitro and in vivo reversal of resistance to 5fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation, Br. J. Cancer, vol.97, pp.919-926, 2007. ,
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging, Cancer Chemother. Pharmacol, vol.61, pp.395-405, 2008. ,
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes, Ann Pharmacother, vol.52, pp.792-800, 2018. ,
Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes, Cancer Immunol Res, vol.2, pp.436-447, 2014. ,
Chemoimmunotherapy: reengineering tumor immunity, Cancer Immunol. Immunother, vol.62, pp.203-216, 2013. ,
The interplay of immunotherapy and chemotherapy: harnessing potential synergies, Cancer Immunol Res, vol.3, pp.436-443, 2015. ,
Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy, Lung Cancer, vol.99, pp.4-10, 2016. ,
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response, J. Exp. Med, vol.201, pp.1591-1602, 2005. ,
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations, J Transl Med, vol.7, p.58, 2009. ,
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism, J. Immunol, vol.183, pp.137-144, 2009. ,
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy, J. Natl. Cancer Inst, vol.110, pp.777-786, 2018. ,
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology, Critical Reviews in Oncology / Hematology, vol.129, pp.1-12, 2018. ,
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future, Toxicol. Appl. Pharmacol, vol.299, pp.70-77, 2016. ,
Immunological mechanism underlying the immune response to recombinant human protein therapeutics, Trends Pharmacol. Sci, vol.31, pp.53-59, 2010. ,
Nanoparticles and the immune system, Endocrinology, vol.151, pp.458-465, 2010. ,
Antibodies against liposomes in normal and immune-defective mice, The Journal of Immunology, vol.128, pp.1603-1607, 1982. ,
Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro, Molecules, vol.23, p.1700, 2018. ,
Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon, Immunobiology, vol.218, pp.725-732, 2013. ,
A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors, Nano Res, vol.8, pp.1505-1521, 2015. ,
Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles, Bioconjug. Chem, vol.26, pp.812-816, 2015. ,
Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles, Mol. Pharm, vol.10, pp.3525-3530, 2013. ,
Nanoscale artificial antigen presenting cells for T cell immunotherapy, Nanomedicine, vol.10, pp.119-129, 2014. ,
Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy, Vaccine, vol.20, issue.4, pp.46-51, 2002. ,
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, Clin. Cancer Res, vol.7, pp.3025-3030, 2001. ,
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and-Extrinsic Factors, Immunity, vol.44, pp.1255-1269, 2016. ,
Barriers to drug delivery in solid tumors, Sci. Am, vol.271, pp.58-65, 1994. ,
Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells, Adv Funct Mater, vol.25, pp.4183-4194, 2015. ,
The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel, Nanomedicine, vol.11, pp.207-218, 2015. ,
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer, J. Am. Chem. Soc, vol.138, pp.16686-16695, 2016. ,
Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies, Cancer Res, vol.78, 2018. ,
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery, Nature Biotechnology [Internet], vol.36, pp.707-716, 2018. ,
Metal based nanoparticles as cancer antigen delivery vehicles for macrophage based antitumor vaccine, Vaccine, vol.34, pp.957-967, 2016. ,
Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity, J. Natl. Cancer Inst, 2018. ,
Walking the line: The fate of nanomaterials at biological barriers, Biomaterials, vol.174, pp.41-53, 2018. ,
A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells, Int J Mol Sci, vol.18, p.2134, 2017. ,
Hazard and risk assessment strategies for nanoparticle exposures: how far have we come in the past 10 years?, vol.7, p.376, 2018. ,